These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://myaggde533291.blogprodesign.com/60332223/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide